B Group, Inc. disclosed a new stake in Bright Minds Biosciences (DRUG +5.15%) in its May 15, 2026, SEC filing, acquiring 67,500 shares—an estimated $5.43 million trade based on quarterly average pricing.
What happened
According to a May 15, 2026, SEC filing, B Group, Inc. initiated a new position in Bright Minds Biosciences, purchasing 67,500 shares. The estimated transaction value is $5.43 million, calculated using the average closing price for the first quarter of 2026. The value of the stake at quarter-end was $4.93 million, a figure that includes both share purchases and movement in the company’s stock price during the period.
What else to know
- This is a new position for B Group, Inc., representing roughly 4% of reportable AUM as of March 31, 2026.
- Top five holdings after the filing:
- NASDAQ: ADMA: $28.90 million (21.4% of AUM)
- NASDAQ: PALI: $19.97 million (14.8% of AUM)
- NASDAQ: PRAX: $10.71 million (7.9% of AUM)
- NASDAQ: CLLS: $10.40 million (7.7% of AUM)
- NASDAQ: ZLAB: $8.48 million (6.3% of AUM)
- As of Thursday, Bright Minds Biosciences shares were priced at $83.24, up nearly 175% over the past year and well outperforming the S&P 500, which is instead up about 25%.
Company Overview
| Metric | Value |
|---|---|
| Price (as of market close May 14, 2026) | $83.24 |
| Market Capitalization | $815 million |
| Net Income (TTM) | ($19.8 million) |
Company Snapshot
- DRUG develops selective 5-HT receptor agonists targeting epilepsy, pain, and neuropsychiatric disorders, with a portfolio focused on 5-HT2C, 5-HT2A, and 5-HT2C/A compounds.
- The firm operates a pre-clinical biotechnology model, generating value through research collaborations and intellectual property development rather than product sales.
- It targets patients with severe neurological and psychiatric conditions, collaborating with research institutions and healthcare partners to advance clinical applications.
Bright Minds Biosciences is a pre-clinical biotechnology company specializing in the development of next-generation serotonin-based therapeutics for neurological and neuropsychiatric conditions. The company leverages strategic collaborations with leading medical research institutions to accelerate innovation and expand its intellectual property portfolio. With a focus on high unmet medical needs, Bright Minds aims to establish a competitive edge through targeted drug development and scientific partnerships.
What this transaction means for investors
B Group is stepping into Bright Minds during a massive run higher, suggesting it sees additional upside tied to the company's drug pipeline (given the nature of pre-revenue biotechs). The company's most important asset remains BMB-101, a serotonin receptor agonist being developed for drug-resistant epilepsies. Management has been accelerating development efforts, with research and development spending climbing to C$18.7 million during the first six months of fiscal 2026, up from C$3.6 million a year earlier as clinical and preclinical programs advanced.
Just as important, Bright Minds ended March with roughly C$309.7 million in cash and cash equivalents after completing a January equity offering that raised about $175 million. That gives the company substantial resources to fund development without the near-term financing pressure that often weighs on early-stage biotech firms. For long-term investors, this is still a high-risk, high-reward story. The company has no commercial revenue and remains loss-making. But with a well-funded balance sheet and pipeline progress, there are reasons to be bullish.
